Mark Weeks

[Mark Weeks @Scotch1]

Congratulations @Procyrion ! @CooleyLLP is proud to support you and your efforts to improve lives of patients with cardiac and renal impairment. Procyrion Closes $57.7 Million in Series E Financing https://t.co/uWCSoBeqJ4

[Mark Weeks @Scotch1]

Congratulations to @BigHatBio!

[BigHat Biosciences @BigHatBio]

🚀 NEWS: We’ve entered a research collaboration with @abbvie to leverage #ArtificialIntelligence and #MachineLearning to develop next-generation therapeutic antibodies in oncology and neuroscience.

https://t.co/3c23AgCr2S

[Cooley LLP @CooleyLLP]

This article on #CooleyGO addresses key contractual issues that you may need to navigate when reviewing or negotiating agreements with providers of generative #AI tools.

💡 Get the insight from Cooley here: https://t.co/IEENIiYDVt

[Mark Weeks @Scotch1]

Check out @CooleyLLP Q1 Venture Financing Report

[Cooley LLP @CooleyLLP]

Cooley's Q1 2023 Venture Financing Report is now live, reflecting a decline in deal count and invested #capital throughout the quarter, in addition to generally favorable #deal terms for companies.

View the full #CooleyGO report here: https://t.co/lcdC7ejo6p

#venturecapital

[Mark Weeks @Scotch1]

Join @CooleyLLP on May 4th at our one day Healthtech Conference in San Francisco. Insights on business, financings, operations in challenging times with VCs/executives/entrepreneurs.

[Cooley LLP @CooleyLLP]

There is still time to register for our 13th Annual #Healthtech Conference in San Francisco on 5/4, during which top executives, investors, entrepreneurs and thought leaders will unpack the key drivers affecting the #healthtech industry + more. 👉 https://t.co/QwexyYx0Op

[Mark Weeks @Scotch1]

Congratulations @spiraltx !

[Spiral Therapeutics @spiraltx]

🚀 We are thrilled to announce our acquisition of assets from Otonomy, strengthening our inner ear disorders pipeline!

We also welcome biotech veterans Frederic Guerard and Tony Adamis, to our Board of Directors. https://t.co/AqkYPUG4kp

[Cooley LLP @CooleyLLP]

We have compiled a compendium of informational resources intended to help clients and companies navigate the evolving situation of the Silicon Valley Bank closure. We will update this space as additional guidance and analysis is published.

View more here: https://t.co/MibZXTu8If

[Mark Weeks @Scotch1]

SVB updates/FAQ from the FDIC: https://t.co/3tE0smequf via @FDICgov

[Mark Weeks @Scotch1]

SVB UPDATE: @CooleyLLP has posted two forms of short-term promissory notes for Delaware corporations that are funding loans for payroll and similar obligations. One is secured and one is unsecured. https://t.co/Z2I5UZdhOn via @CooleyLLP

[Mark Weeks @Scotch1]

Here is @CooleyLLP's public resource page for all things SVB-related. Check back frequently! https://t.co/aIovPtA2jv via @CooleyLLP

[Cooley LLP @CooleyLLP]

As a resource to the community, we have posted two forms of short-term promissory notes for Delaware corporations that are funding loans for payroll and similar obligations. One is secured and one is unsecured.

Read more on #CooleyGO here: https://t.co/eLoI2sUkn1

[Kite, a Gilead Company @KitePharma]

#NEWS: Announcing the completion of the previously announced transaction to acquire @TmunityTx, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

[Mark Weeks @Scotch1]

Congratulations to the @TmunityTx team and their investors. @CooleyLLP is proud to have supported you on your journey.

[Tmunity Therapeutics @TmunityTx]

Tmunity has been acquired by Kite, a Gilead Company. Follow @KitePharma for updates.

[Mark Weeks @Scotch1]

For the third consecutive year, Cooley has secured its spot as the #1 law firm representing companies in venture capital financings in the US and globally. The firm was additionally ranked first overall in several industry sectors, including pharma and biotech, and healthcare.

[Cooley LLP @CooleyLLP]

🏆 For the third consecutive year, Cooley has earned its spot as the #1 law firm representing companies in venture capital financings in the US and globally as part of @PitchBook’s 2022 Annual Global League Tables. Way to go, #TeamCooley. Read more: https://t.co/gNYUjy865f

[Mark Weeks @Scotch1]

Congrats to the @OrcaBio team for your continued progress in bringing next generation cell therapies to patients!

[Orca Bio @OrcaBio]

Our CEO, Ivan Dimov, recently sat down with @NasdaqExchange at #JPM23 to share his thoughts on Orca Bio's mission and progress building next generation cell therapies. Watch here:

[Mark Weeks @Scotch1]

Congratulations to @spiraltx!
Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière's Disease https://t.co/yhT2RFqpke

[Mark Weeks @Scotch1]

Congratulations @APOLLO_ENDO! We @CooleyLLP are proud to have supported you throughout your journey!

[Mark Weeks @Scotch1]

Congratulations @BigHatBio on your collaboration with @Merck. @CooleyLLP is thrilled to support your continued success.

[BigHat Biosciences @BigHatBio]

We are thrilled to share that BigHat and @Merck are working together on a research collaboration to advance next-generation antibody therapeutics to patients.

Our co-founders @MarkDePristo and @peytongreenside spoke with @GabrielleMasso9 at @FierceBiotech.
[See link in reply]

[Cooley LLP @CooleyLLP]

Congratulations to partner Calise Cheng, who has been named @RecorderTweets's Attorney of the Year! Partners Christa Anderson + Jamie Leigh were also recognized as Women Leaders in Tech Law. 🎉🎉🎉

Read more: https://t.co/c4yAhQSI8D

#tech #leadership

[Mark Weeks @Scotch1]

Congratulations Vaxcyte! @CooleyLLP is proud to support your game changing approach to vaccines!

[Cooley LLP @CooleyLLP]

A Cooley team advised Vaxcyte, a clinical-stage vaccine innovation company, on its underwritten public offering of common stock and pre-funded warrants, with aggregate gross proceeds to Vaxcyte of $690 million.

➡️ Read more: https://t.co/tj0endmoRa